Extracellular matrix
Extracellular matrix - Engitix Therapeutics Ltd, a UCL biotechnology spinout accelerating fibrosis and solid tumour treatments using a proprietary drug discovery platform, has expanded its multi-million-pound collaboration with Japanese pharmaceutical firm Takeda. The second collaboration with Takeda is focused on developing new drug treatments for fibrostenotic inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. Under the terms of this agreement, Engitix and Takeda will collaborate in the confirmation and validation of drug targets and the preclinical development of therapeutics in IBD using Engitix's unique extracellular matrix (ECM) discovery platform. The ECM is the bioactive scaffold that provides structural and biochemical support to cells within human tissues and organs. Takeda will have exclusive rights to develop and commercialise certain clinical candidate drugs generated against validated targets arising from the collaboration. Engitix will be eligible to receive a total of up to approximately $300 million (US) for the achievement of preclinical, development, regulatory and commercial milestones over the course of the partnership, as well as further royalty payments based on sales of commercialised products. This agreement builds on the collaboration between the companies announced in mid-2020, worth up to $500 million, for the discovery and development of novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
